In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice

Journal of Chemotherapy

Volumn 22, Issue 4, 2010, Pages 259-263

  Valeria Dos Santos K ^a   Roque De Carvalho, M A ^a   Amancio Martins, W ^a   Coutinho, S C ^a   Bahia, J L ^a   Lopes De Andrade, J P ^a   Morais Apolonio A C ^a   Cara, D C ^a   Galuppo Diniz, C ^b   Nicoli, J R ^a   De Macêdo Farias, Luiz ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Bacteroides fragilis; Ertapenem; Gnotobiotic mice; Piperacillin tazobactam; Resistant strains; Virulence

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; ERTAPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTEROIDES FRAGILIS; BACTEROIDES INFECTION; CONTROLLED STUDY; GNOTOBIOTICS; IN VITRO STUDY; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT;

EID: 78650239051     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.4.259     Document Type: Article

References (26)

1. Finegold SM. Overview of clinically important anaerobes. Clin Infect Dis 1995; 20 (Suppl 2): 205-7.
2. Sghir A, Gramet G, Suau A, Rochet V, Pochart P, Dore J. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl Environ Microbiol 2000; 66: 2263-6.
3. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007; 51: 1649-55.
4. Löfmark S, Jemberg C, Billström H, Andersson DI, Edlund C. Restored fitness leads to long-term persistence of resistant Bacteroides strains in the human intestine. Anaerobe 2008; 14: 157-60.
5. van der Waaij D, Nord CE. Development and persistence of multi-resistance to antibiotics in bacteria; an analysis and a new approach to this urgent problem. Int J Antimicrob Agents 2000; 16: 191-197.
6. Perry CM, Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 1999; 57: 805-843.
7. Nord CE, Brismar B, Kasholm-Tengve B, Tunevall G. Effect of piperacillin/tazobactam treatment on human bowel microflora. J Antimicrob Chemother 1993; 31 Suppl A: 61-5.
8. Pletz MW, Rau M, Bulitta J, De Roux A, Burkhardt O, Kruse G, et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48: 3765-72.
9. Elliott E, Brink AJ, van Greune J, Els Z, Woodford N, Turton J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006; 42: e95-8.
10. Diniz CG, Cara DC, Nicoli JR, Farias LM, de Carvalho MAR. Effect of metronidazole on the pathogenicity of resistant Bacteroides strains in gnotobiotic mice. Antimicrob Agents Chemother 2000; 44: 2419-23.
11. Lorian V, Gemmel GC. Effect of low antibiotic concentrations on bacteria: effects on ultrastructure, virulence, and susceptibility to immunodefenses. In: Lorian, V., ed. Antibiotics in laboratory medicine. Baltimore, MD: Williams & Wilkins. 1991: p493-555.
12. Diniz CG, Farias LM, Carvalho MA, Rocha ER, Smith CJ. Differential gene expression in a Bacteroides fragilis metronidazole-resistant mutant. J Antimicrob Chemother 2004; 54: 100-8.
13. NCCLS. Methods for Antimicrobial Susceptibility Testing for Anaerobic Bacteria, 6th edn. Approved Standard. NCCLS publication M11-A6. 2004. Wayne, PA: National Committee for Clinical Laboratory Standards.
14. Bryson L, Szybalski W. Microbial selection. Science 1952;116:45-51.
15. Dos Santos KV, Diniz CG, Coutinho SC, Apolônio ACM, Sousa-Gaia LG, Nicoli JR, et al. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures. J Med Microbiol 2007; 56: 798-802
16. Gillespie SH, Begg NT, Bannister BA. Infections of the liver. In: Gillespie, S.H., Begg, N.T., Bannister, B.A. Infectious disease. Oxford; Maiden, USA: Blackwell Science. 2000: 191-214.
17. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
18. Moss DW. Perspectives in Alkaline Phosphatase Research. Clin Chem 1992; 38: 2486-2492.
19. Hoeprich, PD. Manifestations of Infectious Diseases. In: HOEPRICH, P.D. Editor. Infectious Diseases: A guide to the Understanding and Management of Infectious Processes. USA: Harper & Row. 1972: p.57-70.
20. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Semm aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-6.
21. Katsandri A, Papaparaskevas J, Pantazatou A, Petrikkos GL, Thomopoulos G, Houhoula DP, et al. Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains. J Clin Microbiol 2006;44: 3465-7.
22. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2: 489-93.
23. Claros MC, Claros ZC, Hecht DW, Citron DM, Goldstein EJ, Silva J JR, et al. Characterization of the Bacteroides fragilis pathogenicity island in human blood culture isolates. Anaerobe 2006; 12: 17-22.
24. Edwards R, Greenwood D. Distinctive outer membrane protein and lipopolysaccharide composition of Bacteroides fragilis strains that produce metallo-beta-lactamase. Anaerobe 1997, 3: 233-6.
25. Diniz CG, Arantes RM, Cam DC, Lima FL, Nicoli JR, Carvalho MAR, et al. Enhanced pathogenicity of susceptible Bacteroides fragilis group subjected to low doses of metronidazole. Microbes Infect 2003; 5: 19-26.
26. Martinez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 2002; 15: 647-79.